The effect of nanocurcumin and omega-3 supplementation on quality of life in patients with asthma

Our study aims to identify an adjunctive therapy for asthma patients that is both cost-effective and safe to limit the need to add more expensive drug therapies such as biologics.

A clinical trial with a control group and a double-blind randomized trial on 88 patients ANCOVA will be used to investigate the effect of intervention on quantitative outcomes for controlling confounding variables. Blocks of four were done based on age classification.

The study will be conducted in a double-blind manner at Hazrat Rasool Akram Hospital. Food recall, quality of life questionnaires, asthma control questionnaires, international physical activity questionnaires, consent forms, and general information will be recorded before and after the intervention.

Inclusion criteria: 1) Patients with asthma diagnosed by a doctor 2) Asthma patients with an age range of 15 to 60 years Non-entry criteria: 1) Users of systemic drugs, immunosuppressive drugs 2) People with COPD, cardiovascular disease, kidney disease, digestive disease, liver disease, autoimmune disease, reflex 3) Pregnant and lactating women 4) Addicted people and tobacco users, including hookah and smoking, etc. 5) Allergy/intolerance to curcumin, fish oil 6) Consumption of food supplements and antioxidants from 2 months before and during the study

The intervention group consumes a 40 mg nanocurcumin supplement and a 1000 mg omega _3 daily for 8 weeks. The control group consumes a placebo 40mg nanocurcumin and a placebo 1000mg omega_3 daily for 8 weeks.

Quality of life of patients with asthma. Measurement of exhaled nitric oxide through the FeNo device

Patients who meet the criteria for entering the study will be divided to groups A and B, based on a randomized list (by the method of blocks of four obtained from the Random number calculator computer program). In order to make a placebo, coordination will be done with Karen and Elixir Nano Sina pharmaceutical companies And it is requested that the drug manufacturer put one of the letters A or B on the drug or placebo and the other letters on the other by using a lottery by throwing a coin.

This interventional study will be conducted in a double-blind manner. Blinding includes patients and researchers. Coordination will be done with Karen and Vaxir Nano Sina pharmaceutical companies for the preparation of the placebo. The drug manufacturer will place one of the letters A or B on the drug or placebo by throwing a coin, and this will be kept confidential until the end of the intervention. It keeps itself. That means the therapist will not know whether the package is a supplement or a placebo. The placebo capsules will be completely similar to the capsules of the intervention group in terms of color, smell and shape.